Skip to Content
Merck

Epidemiology of candidemia in Latin America: a laboratory-based survey.

PloS one (2013-03-26)
Marcio Nucci, Flavio Queiroz-Telles, Tito Alvarado-Matute, Iris Nora Tiraboschi, Jorge Cortes, Jeannete Zurita, Manuel Guzman-Blanco, Maria Elena Santolaya, Luis Thompson, Jose Sifuentes-Osornio, Juan I Echevarria, Arnaldo L Colombo
ABSTRACT

The epidemiology of candidemia varies depending on the geographic region. Little is known about the epidemiology of candidemia in Latin America. We conducted a 24-month laboratory-based survey of candidemia in 20 centers of seven Latin American countries. Incidence rates were calculated and the epidemiology of candidemia was characterized. Among 672 episodes of candidemia, 297 (44.2%) occurred in children (23.7% younger than 1 year), 36.2% in adults between 19 and 60 years old and 19.6% in elderly patients. The overall incidence was 1.18 cases per 1,000 admissions, and varied across countries, with the highest incidence in Colombia and the lowest in Chile. Candida albicans (37.6%), C. parapsilosis (26.5%) and C. tropicalis (17.6%) were the leading agents, with great variability in species distribution in the different countries. Most isolates were highly susceptible to fluconazole, voriconazole, amphotericin B and anidulafungin. Fluconazole was the most frequent agent used as primary treatment (65.8%), and the overall 30-day survival was 59.3%. This first large epidemiologic study of candidemia in Latin America showed a high incidence of candidemia, high percentage of children, typical species distribution, with C. albicans, C. parapsilosis and C. tropicalis accounting for the majority of episodes, and low resistance rates.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Fluconazole, ≥98% (HPLC), powder
Fluconazole, European Pharmacopoeia (EP) Reference Standard
Supelco
Fluconazole, Pharmaceutical Secondary Standard; Certified Reference Material
Fluconazole for peak identification, European Pharmacopoeia (EP) Reference Standard